Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 330

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Open access
Zhang, Sen, Anjum, Rana, Squillace, Rachel, Nadworny, Sara, Zhou, Tianjun, Keats, Jeff, Ning, Yaoyu, Wardwell, Scott D., Miller, David, Song, Youngchul, Eichinger, Lindsey, Moran, Lauren, Huang, Wei-Sheng, Liu, Shuangying, Zou, Dong, Wang, Yihan, Mohemmad, Qurish, Jang, Hyun Gyung, Ye, Emily, Narasimhan, Narayana, Wang, Frank, Miret, Juan, Zhu, Xiaotian, Clackson, Tim, Dalgarno, David, Shakespeare, William C., Rivera, Victor M.·2016·Clinical Cancer Research

Abstract

Purpose: Non–small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary resistance mutations in ALK or disease progression in the brain. Mutations that confer resistance to second-generation ALK TKIs ceritinib and alectinib have also been identified. Here, we report the structure and first comprehensive preclinical evaluation of the next-generation ALK TKI brigatinib. Experimental Design: A kinase screen was performed to evaluate the selectivity profile of brigatinib. The cellular and in vivo activities of ALK TKIs were compared using engineered and cancer-derived cell lines. The brigatinib–ALK co-structure was determined. Results: Brigatinib potently inhibits ALK and ROS1, with a high degree of selectivity over more than 250 kinases. Across a panel of ALK+ cell lines, brigatinib inhibited native ALK (IC50, 10 nmol/L) with 12-fold greater potency than crizotinib. Superior efficacy of brigatinib was also observed in mice with ALK+ tumors implanted subcutaneously or intracranially. Brigatinib maintained substantial activity against all 17 secondary ALK mutants tested in cellular assays and exhibited a superior inhibitory profile compared with crizotinib, ceritinib, and alectinib at clinically achievable concentrations. Brigatinib was the only TKI to maintain substantial activity against the most recalcitrant ALK resistance mutation, G1202R. The unique, potent, and pan-ALK mutant activity of brigatinib could be rationalized by structural analyses. Conclusions: Brigatinib is a highly potent and selective ALK inhibitor. These findings provide the molecular basis for the promising activity being observed in ALK+, crizotinib-resistant patients with NSCLC being treated with brigatinib in clinical trials. Clin Cancer Res; 22(22); 5527–38. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-0569

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 330

Metadata

Authors
Zhang, S., Anjum, R., Squillace, R., Nadworny, S., Zhou, T., Keats, J., Ning, Y., Wardwell, S. D., Miller, D., Song, Y., Eichinger, L., Moran, L., Huang, W.-S., Liu, S., Zou, D., Wang, Y., Mohemmad, Q., Jang, H. G., Ye, E., Narasimhan, N., Wang, F., Miret, J., Zhu, X., Clackson, T., Dalgarno, D., Shakespeare, W. C., & Rivera, V. M.
Venue
Clinical Cancer Research
Published
2016-11-14
Volume
22
Issue
22
Pages
5527-5538
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2533300620
Cited by
330
References
5
FWCI
31.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-0569
The paper
Zhang, S., Anjum, R., Squillace, R., Nadworny, S., Zhou, T., Keats, J., Ning, Y., Wardwell, S. D., Miller, D., Song, Y., Eichinger, L., Moran, L., Huang, W.-S., Liu, S., Zou, D., Wang, Y., Mohemmad, Q., Jang, H. G., Ye, E., . . . Rivera, V. M. (2016). The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-0569

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.